Letter: Autoimmune hepatitis and metabolic syndrome‐associated disease development – a US cohort study

Liling Deng,Wuquan Deng

DOI: https://doi.org/10.1111/apt.17231

2022-01-01

Abstract:LINKED CONTENT This article is linked to Jalal et al papers. To view these articles, visit

What problem does this paper attempt to address?

Letter: the association between chronic viral hepatitis and metabolic syndrome.

Jian Zhao,Lingling Fang,Yawen Song,Chun Liang

DOI: https://doi.org/10.1111/apt.15037

IF: 9.524

2019-01-01

Alimentary Pharmacology & Therapeutics

Abstract:Linked Content This article is linked to Kuo et al and Kuo and Lu papers. To view these articles, visit and .
A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Jiang-Shan Lian,Wei Liu,Shao-Rui Hao,De-Ying Chen,Yin-Yin Wang,Jian-Le Yang,Hong-Yu Jia,Jian-Rong Huang

DOI: https://doi.org/10.1016/s1499-3872(15)60393-9

IF: 3.355

2015-01-01

Hepatobiliary & Pancreatic Diseases International

Abstract:BACKGROUND:Because of the diversity of the clinical and laboratory manifestations, the diagnosis of autoimmune liver disease (AILD) remains a challenge in clinical practice. The value of metabolomics has been studied in the diagnosis of many diseases. The present study aimed to determine whether the metabolic profiles, based on ultraperformance liquid chromatography-mass spectrometry (UPLC-MS), differed between autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC), to identify specific metabolomic markers, and to establish a model for the diagnosis of AIH and PBC.METHODS:Serum samples were collected from 20 patients with PBC, 19 patients with AIH, and 25 healthy individuals. UPLC-MS data of the samples were analyzed using principal component analysis, partial least squares discrimination analysis and orthogonal partial least squares discrimination analysis.RESULTS:The partial least squares discrimination analysis model (R2Y=0.991, Q2=0.943) was established between the AIH and PBC groups and exhibited both sensitivity and specificity of 100%. Five groups of biomarkers were identified, including bile acids, free fatty acids, phosphatidylcholines, lysolecithins and sphingomyelin. Bile acids significantly increased in the AIH and PBC groups compared with the healthy control group. The other biomarkers decreased in the AIH and PBC groups compared with those in the healthy control group. In addition, the biomarkers were downregulated in the AIH group compared with the PBC group.CONCLUSIONS:The biomarkers identified revealed the pathophysiological changes in AILD and helped to discriminate between AIH and PBC. The predictability of this method suggests its potential application in the diagnosis of AILD.
Letter: Vitamin D Deficiency and Autoimmune Hepatitis – from Research to Treatment

Jiamei Wang,Jianjiang Xu,Xiaoping Shao,Zonggui Wu,Chun Liang

DOI: https://doi.org/10.1111/apt.15147

IF: 9.524

2019-01-01

Alimentary Pharmacology & Therapeutics

Abstract:Linked Content This article is linked to Ebadi et al papers. To view these articles, visit https://doi.org/10.1111/apt.15029 and https://doi.org/10.1111/apt.15154 .
Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis

Kehui Liu,Mingyang Feng,Wanqing Chi,Zhujun Cao,Xiaoyin Wang,Yezhou Ding,Gangde Zhao,Ziqiang Li,Lanyi Lin,Shisan Bao,Hui Wang

DOI: https://doi.org/10.1007/s12072-024-10727-w

IF: 9.029

2024-09-11

Hepatology International

Abstract:This cross-sectional study aimed to investigate the impact of metabolic-associated diseases (MADs) on patients with autoimmune hepatitis (AIH).

gastroenterology & hepatology
Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease

Jannis Kountouras,Stergios A. Polyzos,Evangelos Kazakos,Ioannis S. Papanikolaou,Christos Liatsos,Elisabeth Vardaka,Dimitrios Tzilves,Efthimia Vlachaki

DOI: https://doi.org/10.1111/apt.18066

IF: 9.524

2024-07-03

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Dominik et al papers. To view these articles, visit https://doi.org/10.1111/apt.17945 and https://doi.org/10.1111/apt.18144

pharmacology & pharmacy,gastroenterology & hepatology
Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply

Bernhard Scheiner,Nina Dominik,Mattias Mandorfer

DOI: https://doi.org/10.1111/apt.18144

IF: 9.524

2024-07-03

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Dominik et al papers. To view these articles, visit https://doi.org/10.1111/apt.17945 and https://doi.org/10.1111/apt.18066

pharmacology & pharmacy,gastroenterology & hepatology
Concurrence and Impact of Hepatic Steatosis on Chronic Hepatitis B Patients: a Systematic Review and Meta-Analysis

Daixi Jiang,Can Chen,Xiaoxiao Liu,Chenyang Huang,Danying Yan,Xiaobao Zhang,Yuqing Zhou,Yushi Lin,Yiyi Zhou,Zhou Guan,Cheng Ding,Lei Lan,Changtai Zhu,Jie Wu,Lanjuan Li,Shigui Yang

DOI: https://doi.org/10.21037/atm-21-3052

IF: 3.616

2021-01-01

Annals of Translational Medicine

Abstract:Background: The association between hepatic steatosis (HS) and chronic hepatitis B (CHB) remains controversial. We performed a systematic review and meta-analysis to investigate the latest concurrence rate and impact of HS on CHB patients. Methods: Relevant studies were identified by searching PubMed, EMBASE, and the Cochrane Library from January 1, 2000 to December 2, 2020. We calculated the pooled prevalence of HS in CHB patients using a random effects model. A subgroup analysis was performed to explore the impact of HS on CHB patients. This study is registered with PROSPERO (no. CRD42021242584). Results: A total of 98 studies with a population of 48,472 patients were included. The global prevalence of HS in CHB patients was 34.93% [95% confidence interval (CI): 32.01-37.90%]. Overweight status, hypertension, diabetes, hyperlipidemia, and metabolic syndrome showed a higher risk for developing HS in CHB patients, while positive hepatitis B e antigen (HBeAg) status was negatively associated with the presence of HS [odds ratio (OR) =0.81, 95% CI: 0.70-0.93]. The pooled analysis showed no significant association between HS and fibrosis progression (OR =0.68, 95% CI: 0.44-1.05). However, the coexistence of HS was negatively associated with the antiviral therapy response in CHB patients, including virological response (OR =0.69, 95% CI: 0.48-0.99) and alanine aminotransferase (ALT) normalization (OR =0.44, 95% CI: 0.28-0.69). Conclusions: The global prevalence of HS in CHB patients is higher than previously estimated. The concurrence of HS could impact the replication of HBV and the effectiveness of antiviral therapy in CHB patients. However, coexistence with HS did not show a higher risk of developing advanced fibrosis in CHB patients.
Metabolomic Signatures of Autoimmune Hepatitis in the Development of Cirrhosis

Shan-shan Li,Ming Niu,Jing Jing,Ying Huang,Zi-teng Zhang,Shuai-shuai Chen,Ge-zi Shi,Xian He,Hai-zhu Zhang,Xiao-he Xiao,Zheng-sheng Zou,Yue-cheng Yu,Jia-bo Wang

DOI: https://doi.org/10.3389/fmed.2021.644376

IF: 3.9

2021-03-12

Frontiers in Medicine

Abstract:Objectives: Autoimmune hepatitis (AIH) can progress into severe outcomes, i.e., decompensated cirrhosis, from remarkable and persistent inflammation in the liver. Considering the energy-expending nature of inflammation, we tried to define the metabolomics signatures of AIH to uncover the underlying mechanisms of cirrhosis development and its metabolic biomarkers. Methods: Untargeted metabolomics analysis was performed on sera samples from 79 AIH patients at the stages (phenotypes) of non-cirrhosis ( n = 27), compensated cirrhosis ( n = 22), and decompensated cirrhosis ( n = 30). Pattern recognition was used to find unique metabolite fingerprints of cirrhosis with or without decompensation. Results: Out of the 294 annotated metabolites identified, 2 metabolic fingerprints were found associated with the development of cirrhosis (independent of the decompensated state, 42 metabolites) and the evolution of decompensated cirrhosis (out of 47 metabolites), respectively. The cirrhosis-associated fingerprints (eigenmetabolite) showed better capability to differentiate cirrhosis from non-cirrhosis patients than the aminotransferase-to-platelet ratio index. From the metabolic fingerprints, we found two pairs of metabolites (Mesobilirubinogen/6-Hydroxynicotinic acid and LysoPA(8:0/0:0)/7alpha-Hydroxycholesterol) calculated as ratio of intensities, which revealed robust abilities to identify cirrhosis or predict decompensated patients, respectively. These phenotype-related fingerprint metabolites featured fundamental energy supply disturbance along with the development of AIH cirrhosis and progression to decompensation, which was characterized as increased lipolysis, enhanced proteolysis, and increased glycolysis. Conclusions: Remodeling of metabolism to meet the liver inflammation-related energy supply is one of the key signatures of AIH in the development of cirrhosis and decompensation. Therefore, drug regulation metabolism has great potential in the treatment of AIH.

medicine, general & internal
Advances in Study on Metabolic Syndrome and Viral Hepatitis

Yuwei DONG,Lungen LU

DOI: https://doi.org/10.3969/j.issn.1008-7125.2013.09.013

2013-01-01

Abstract:Metabolic syndrome comprises a group of correlated clinical features which have insulin resistance (IR) as a common pathogenic determinant. It can lead to type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disorders. Some studies have shown that metabolic syndrome is a risk factor for hepatic tissue injure in patients with chronic viral hepatitis, but the conclusion is still a controversial issue. This article reviewed the advances in study on metabolic syndrome and viral hepatitis.
Causal effects of plasma metabolites on autoimmune hepatitis (AIH): a bidirectional two-sample mendelian randomization study

Zhen Zheng,Dahua Chen,Jiaming Lv,Juan Du,Kaitai Liu

DOI: https://doi.org/10.1038/s41598-024-74387-4

IF: 4.6

2024-10-04

Scientific Reports

Abstract:Autoimmune hepatitis(AIH) is a chronic progressive inflammatory liver disease induced by loss of immune tolerance. The role of circulating metabolites in disease pathogenesis is unclear. This study aimed to investigate potential causal links between plasma metabolites and AIH risk by employing a two-sample Mendelian randomization approach. A comprehensive bidirectional two-sample Mendelian randomization analysis was conducted using genome-wide significant variant-metabolite and variant-AIH associations in European ancestry individuals. Various methods assessed causal relationships among 1400 metabolites and AIH, incorporating sensitivity analyses to evaluate pleiotropy and heterogeneity. Fifty-eight metabolites displayed possible associations, including increased AIH risk with genetically predicted higher kynurenine ( p = 2.79 × 10 − 5 , OR: 1.64, 95% CI 1.30–2.07) and a protective effect for the dopamine sulfate ratio ( p = 1.06 × 10 − 5 ,OR: 0.62, 95% CI 0.49–0.79). Reciprocal analysis revealed a causal effect of AIH on kynurenine( p = 2.79 × 10 − 5 , OR: 1.64, 95% CI 1.30–2.07), but not on the dopamine sulfate ratio( p = 0.691, OR: 1.05, 95% CI 0.67–1.64). Our genetics-based approach provides evidence supporting a causal role for specific metabolite levels in AIH risk. The results deliver evidence supporting a causal effect of a specific metabolite ratio(dopamine 4-sulfate/dopamine 3-O-sulfate) on AIH risk. Experimental validation and mechanistic examinations are warranted to confirm findings.

multidisciplinary sciences
Association Between Hepatitis B Virus Infection and Metabolic Syndrome: a Retrospective Cohort Study in Shanghai, China

Yanbing Zhou,Yan Cui,Haiju Deng,Jinming Yu

DOI: https://doi.org/10.1186/1471-2458-14-516

IF: 4.5

2014-01-01

BMC Public Health

Abstract:BACKGROUND:Metabolic syndrome (MS) and hepatitis B (HBV) infection are two major public health problems in China. There are few studies about their association, and the results of these studies are contradictory. We conducted a retrospective cohort study to assess the association between MS and HBV in a Shanghai community-based cohort.METHODS:Nine hundred seventy-six Shanghai residents were recruited from the Putuo community. 480 HBV infections were in exposed group and 496 non-infections in unexposed group. All metabolic-related parameters and hepatitis B serology were tested with routine biochemical or immunological methods. "Exposed" was defined by HBV infection represented by hepatitis B surface antigen (HBsAg) and without anti-virus treatment. "Unexposed" were subjects who didn't infect with HBV (Represented by HBsAg) and no MS when they entered the cohort. MS was defined based on the updated National Cholesterol Education Program Adult Treatment Panel III criteria. The Cox proportional hazards model was used to estimate the hazard ratios (HR) and related 95% confidence intervals (95% CI) for the association between HBV infection and MS over a 20-year follow-up period.RESULTS:Of 976 subjects recruited, 480 had latent HBV infection (exposed subjects). After adjusting for age, the crude HR was 2.46 (95% CI: 1.77, 3.41). After adjusting for potential risk factors of MS (age, gender, smoking, passive smoking, alcohol consumption, physical activity, and diet), the HR was 2.27 (95% CI: 1.52, 3.38).CONCLUSIONS:This 20-year follow-up retrospective cohort study in Shanghai showed a positive association between HBV infection and MS.
Association Between Hepatitis B Virus Infection and Metabolic Syndrome in Southwest China: A Cross-sectional Study

Li-Bo Yan,Juan Liao,Ning Han,Ling-Yun Zhou,Xue-Er Wang,You-Juan Wang,Hong Tang

DOI: https://doi.org/10.1038/s41598-020-62609-4

IF: 4.6

2020-01-01

Scientific Reports

Abstract:The correlation between hepatitis B virus (HBV) infection and metabolic syndrome (MetS) remains to be clarified. In this study, we explored this association in a large population in Southwest China. This was a cross-sectional study, with pooled adult health data. Multivariate logistic regression analysis, controlling for age, sex, HBV status, alanine aminotransferase, and fatty liver, was used to identify predictor(s) of MetS. Of the 96,175 participants, positive HBV was identified in 7984 (8.30%) and MetS in 12,092 (12.57%). The MetS prevalence was lower among HBV positive than negative individuals (11.64% versus 12.66%, P < 0.001). The adjusted odds (aOR) of positive HBV among individuals with MetS was 0.841 (95% confidence interval (CI), 0.771–0.916) in men and 0.834 (95% CI, 0.672–0.925) in women. Elevated triglyceride level, a component of MetS, was inversely associated with HBV status in both men and women: aOR, 0.551 (95% CI, 0.514–0.590) and 0.683 (95% CI, 0.605–0.769), respectively. Among HBV positive individuals, liver cirrhosis was more common among those with than without MetS (4.83% versus 2.93%, respectively; P = 0.002). HBsAg-seropositive are inversely associated with MetS, especially elevated triglycerides. Liver cirrhosis was more common among HBV infection patients with MetS.
Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China

Shaoyuan Lei,Shuohua Chen,Xinyu Zhao,Yanmin Zhang,Kailiang Cheng,Xiaohui Zhang,Zhenyu Wang,Yuanyuan Sun,Shouling Wu,Li Wang

DOI: https://doi.org/10.1007/s12072-020-10086-2

IF: 9.029

2020-09-01

Hepatology International

Abstract:The effect of hepatitis B virus (HBV) infection on diabetes has remained unclear. We thus conducted a prospective cohort study to investigate the association between different HBV infection status and new-onset diabetes in a Chinese population.

gastroenterology & hepatology
Metabolic disorders and hepatitis: Insights from a Mendelian randomization study

Ling-Bo Liang,Xiang-Ping Liu,Ting-Rui Mao,Qiao-Li Su

DOI: https://doi.org/10.4240/wjgs.v16.i6.1775

2024-06-27

World J Gastrointest Surg

Abstract:Background: Hepatitis is a systemic disease that often results in various comorbidities. Meta-bolic disorders, the most common comorbidities in clinical practice, were selected for this study. Aim: To investigate the causal relationship between comorbidities and hepatitis trea-tment outcomes. Methods: A total of 23583378 single nucleotide polymorphisms from 1248743 cases and related summaries of genome-wide association studies were obtained from online public databases. A two-sample Mendelian randomization (MR) was performed to investigate causality between exposure [type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension] and outcome (chronic hepatitis B or C in-fections). Results: The data supported the causal relationship between comorbidities and hepatitis infections, which will affect the severity of hepatitis progression and will also provide a reference for clinical researchers. All three exposures showed a link with progression of both hepatitis B (T2D, P = 0.851; hyperlipidemia, P = 0.596; and hypertension, P = 0.346) and hepatitis C (T2D, P = 0.298; hyperlipidemia, P = 0.141; and hypertension, P = 0.035). Conclusion: The results of MR support a possible causal relationship between different ex-posures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression; however, the potential mechanisms still need to be elucidated.
Supplementary Material For: Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Thin K.N.,Alexandre Tran,Jian Li,Yoosook Lee,Huanming Yang,Rui F.,Liu C,Selwyn Selva Kumar D,Cheung R.C.,Nithesh Kumar H.

DOI: https://doi.org/10.6084/m9.figshare.17881115

2022-01-01

Abstract:Introduction: Chronic hepatitis B (CHB) patients with metabolic syndrome (MetS) may present increased risk of liver-related outcomes (LROs) but prior studies were limited by small sample size and/or conflicting results. Using a systematic review and meta-analytic approach, we aimed to determine the association between MetS and LROs in CHB. Methods: Two researchers independently screened studies from the PubMed, Embase, Web of Science, and Cochrane Library databases from inception to January 21, 2020 and extracted the data. Estimates were pooled using a random-effects model. Results: We screened 2,228 articles and included 10 eligible studies (18,360 CHB patients, 2,557 with MetS). MetS was significantly associated with LROs overall (OR=2.45, 95%CI=1.39-4.32) but not the individual LRO components but subgroup analyses were limited by small study numbers. Discussion/Conclusion: MetS is associated with almost 3 folds higher risk of LROs in CHB and should be considered in management decisions. However, additional studies are needed.
Metabolic syndrome and chronic liver diseases

Yu-Jun Shi,Hong Bu

DOI: https://doi.org/10.11569/wcjd.v21.i27.2759

2013-01-01

World Chinese Journal of Digestology

Abstract:Drastic changes in diet and lifestyle as well as rapid population aging in China have made the morbidity of metabolic syndrome(MetS) quite close to the levels of industrialized countries.MetS is one of the highest risk factors for cardiovascular diseases;accumulating epidemiological data also show that MetS is an independent risk factor of the development of chronic liver cirrhosis and hepatocellular carcinoma.The synergism between MetS and HBV infection is considered to robustly increase the morbidity and mortality of end-stage liver diseases,and this needs particular attention because of the huge HBV-positive population in China.The purpose of this review is to disucss the association between MetS and the development of end-stage liver diseases.
Association of Human Leukocyte Antigen (HLA) Footprints with the Comorbidity of Latent Autoimmune Diabetes in Adults (LADA) and Hepatitis C Virus (HCV) Infection: A Multicenter Cross-Sectional Study

Yujin Ding,Pan Zhang,Tuo Deng,Xiang Yan,Min Zhang,Zhiguo Xie,Gan Huang,Ping Wang,Ting Cai,Xiaoli Zhang,Xinqiang Xiao,Ying Xia,Bingwen Liu,Ya Peng,Xiaohan Tang,Min Hu,Yang Xiao,Xia Li,Erik De Clercq,Guangdi Li,Zhiguang Zhou

DOI: https://doi.org/10.1016/j.dsx.2023.102939

2023-01-01

Diabetes & Metabolic Syndrome Clinical Research & Reviews

Abstract:Aims: This study aims to investigate the interplay between hepatitis C virus (HCV) infection and major forms of diabetes: type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA). Methods: This multicenter study analyzed a cohort of 2699 diabetic and 7344 non-diabetic subjects who visited medical centers in China from 2014 to 2021. T1D, T2D, LADA, and HCV were diagnosed using standard procedures. High-throughput sequencing was conducted to identify genetic footprints of human leukocyte antigen (HLA) alleles and haplotypes at the DRB1, DQA1, and DQB1 loci. Results: HCV infection was detected in 3 % (23/766) of LADA patients, followed by 1.5 % (15/977) of T2D patients, 1.4 % (13/926) of T1D patients, and 0.5 % (38/7344) of non-diabetic individuals. HCV prevalence was significantly higher in people with diabetes than in non-diabetic individuals (p < 0.01). HLA alleles (DQB1*060101, DQB1*040101) and haplotypes (DRB1*080302-DQA1*010301-DQB1*060101) in LADA patients with HCV revealed higher frequencies than in LADA patients without HCV (adjusted p < 0.03). Furthermore, a higher risk of diabetes complications was found among LADA patients with HCV infection (p < 0.001). Conclusions: LADA patients are susceptible to HCV infection, potentially associated with certain HLA alleles/haplotypes. Early diagnosis and treatment of HCV infection among people with diabetes are important for the management of severe complications.
Exploring the Bidirectional Relationship Between Metabolic Syndrome and Thyroid Autoimmunity: a Mendelian Randomization Study

Kefan Chen,Wei Sun,Liang He,Wenwu Dong,Dalin Zhang,Ting Zhang,Hao Zhang

DOI: https://doi.org/10.3389/fendo.2024.1325417

IF: 6.055

2024-01-01

Frontiers in Endocrinology

Abstract:Background Observational studies have reported a possible association between metabolic syndrome (MetS) and thyroid autoimmunity. Nevertheless, the relationship between thyroid autoimmunity and MetS remains unclear. The objective of this research was to assess the causal impact of MetS on thyroid autoimmunity through the utilization of Mendelian randomization (MR) methodology.Methods We performed bidirectional MR to elucidate the causal relationship between MetS and their components and thyroid autoimmunity (positivity of TPOAb). Single nucleotide polymorphisms (SNPs) of MetS and its components were obtained from the publicly available genetic variation summary database. The Thyroidomics Consortium conducted a genome-wide association analysis, which provided summary-level data pertaining to thyroid autoimmunity. The study included several statistical methods, including the inverse variance weighting method (IVW), weighted median, simple mode, weight mode, and MR-Egger methods, to assess the causal link. In addition, to ensure the stability of the results, a sensitivity analysis was conducted.Results IVW showed that MetS reduced the risk of developing thyroid autoimmunity (OR = 0.717, 95% CI = 0.584 - 0.88, P = 1.48E-03). The investigation into the causative association between components of MetS and thyroid autoimmune revealed a statistically significant link between triglycerides levels and the presence of thyroid autoimmunity (IVW analysis, OR = 0.603, 95%CI = 0.45 -0.807, P = 6.82E-04). The reverse analysis did not reveal any causal relationship between thyroid autoimmunity and MetS, including its five components.Conclusions We have presented new genetic evidence demonstrating that MetS and its triglyceride components may serve as potential protective factors against thyroid autoimmunity.
Prevalence of Metabolic Syndrome among Adults with Liver Function Injury in Rural Area of Southwest China: A Cross-Sectional Study

Hui Zeng,Hui Lin,Wenyi Liu,Jia Wang,Lingqiao Wang,Chuanfen Zheng,Yao Tan,Yujing Huang,Lixiong He,Jiaohua Luo,Chaowen Pu,Renping Zhang,Xiaohong Yang,Yingqiao Tian,Zhiqun Qiu,Ji-an Chen,Yang Luo,Xiaobin Feng,Guosheng Xiao,Liping Wu,Weiqun Shu

DOI: https://doi.org/10.1038/s41598-017-05791-2

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Abnormal liver function (ALF) plays a key role in metabolic syndrome (MetS), but only few data on the relationship between MetS and the risk factors for ALF (e.g., biotoxins) are available. We aimed to provide the prevalence of MetS and its association with the risk factors for ALF in rural area of Southwest China. A cross-sectional study within the hepatocellular carcinoma cohort was conducted, and included 5493 people with age from 30 to 85 years old. MetS was defined according to the Joint Scientific Statement. We observed that the prevalence of MetS was 31.8% (39.0% in women and 19.8% in men). Logistic regression analysis showed that significantly increased risk of MetS was found in those showing ALF (OR = 3.00, 95% CI: 2.43–3.71). Significantly decreased risk of MetS was found in those with higher HBV DNA titers (OR = 0.49, 95% CI: 0.33–0.74), and in those with higher aflatoxin B1 exposure (estimated daily intake, EDI) (OR = 0.60, 95% CI: 0.53–0.67). No significant change was found in those with higher microcystin-LR exposure (EDI). Therefore, the different risk factors for ALF might exert different effects on MetS. However, there should be an interaction effect existing that might decide the severity of MetS.
Dysregulation of the LPC-ATX-LPA Axis in Autoimmune Hepatitis is Associated with Monocyte Activation

Fan Yang,Xiaoli Fan,Li Yang

DOI: https://doi.org/10.1016/j.jhep.2023.06.010

IF: 25.7

2024-01-01

Journal of Hepatology

Abstract:With great interest, we read the research article from Trovato FM et al.1 In this study, the authors found that reduced lysophosphatidylcholine (LPC) levels are prognostic markers of poor outcome in acute liver failure (ALF). The LPC-autotaxin (ATX)-lysophosphatidylcholinic acid (LPA) pathway appears to modulate innate immune responses in ALF via LPA receptors.

Letter: Autoimmune hepatitis and metabolic syndrome‐associated disease development – a US cohort study

Letter: the association between chronic viral hepatitis and metabolic syndrome.

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Letter: Vitamin D Deficiency and Autoimmune Hepatitis – from Research to Treatment

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply

Concurrence and Impact of Hepatic Steatosis on Chronic Hepatitis B Patients: a Systematic Review and Meta-Analysis

Metabolomic Signatures of Autoimmune Hepatitis in the Development of Cirrhosis

Advances in Study on Metabolic Syndrome and Viral Hepatitis

Causal effects of plasma metabolites on autoimmune hepatitis (AIH): a bidirectional two-sample mendelian randomization study

Association Between Hepatitis B Virus Infection and Metabolic Syndrome: a Retrospective Cohort Study in Shanghai, China

Association Between Hepatitis B Virus Infection and Metabolic Syndrome in Southwest China: A Cross-sectional Study

Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China

Metabolic disorders and hepatitis: Insights from a Mendelian randomization study

Supplementary Material For: Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Metabolic syndrome and chronic liver diseases

Association of Human Leukocyte Antigen (HLA) Footprints with the Comorbidity of Latent Autoimmune Diabetes in Adults (LADA) and Hepatitis C Virus (HCV) Infection: A Multicenter Cross-Sectional Study

Exploring the Bidirectional Relationship Between Metabolic Syndrome and Thyroid Autoimmunity: a Mendelian Randomization Study

Prevalence of Metabolic Syndrome among Adults with Liver Function Injury in Rural Area of Southwest China: A Cross-Sectional Study

Dysregulation of the LPC-ATX-LPA Axis in Autoimmune Hepatitis is Associated with Monocyte Activation